Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market Industry Forecast Reflecting Growth To $11.75 Billion By 2030
The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.
How Will The Market Value Of The Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market Change Between 2026 And 2030?
The nucleic acid and gene therapies in neuromuscular disorders market has experienced significant growth in recent years. It is anticipated to expand from $7.5 billion in 2025 to $8.22 billion in 2026, achieving a compound annual growth rate (CAGR) of 9.7%. Historically, this market’s expansion can be attributed to factors such as limited therapeutic options for NMDs, low awareness regarding gene therapies, the substantial cost of gene therapy development, a shortage of specialized treatment centers, and protracted regulatory approval processes.
The market for nucleic acid and gene therapies in neuromuscular disorders is projected to experience robust expansion over the coming years. This market is anticipated to reach a valuation of $11.76 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 9.4%. The expansion during the forecast period is propelled by factors such as progress in adeno-associated virus and postnatal gene therapies, increased research and development investments in NMDs, an expanding network of hospitals and specialty clinics providing gene therapies, a growing incidence of neuromuscular disorders, and heightened patient awareness along with advocacy efforts. Key trends characterizing this period encompass a greater acceptance of gene therapy techniques, the accelerated development of nucleic acid therapeutics, an intensified focus on rare neuromuscular disorders, increasing capital directed towards personalized medicine approaches, and the enhanced incorporation of sophisticated diagnostic and monitoring instruments.
Download A Free Sample Report For Comprehensive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21233&type=smp
What Core Drivers Are Transforming The Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market?
The anticipated expansion of the nucleic acid and gene therapies in neuromuscular disorders market is driven by the rising occurrence of genetic disorders. These conditions stem from irregularities in an individual’s DNA, which can be inherited or arise from mutations. Various elements contribute to the rise in genetic disorders, including genetic mutations, environmental factors, shifts in lifestyle, and enhanced diagnostic tools. Nucleic acid and gene therapies address genetic disorders by either correcting or substituting faulty genes within neuromuscular conditions, thereby aiming to restore typical bodily functions. For example, data from May 2024, provided by Cure SMA, a US-based non-profit, indicates that the United States currently has about 9,000 to 9,500 individuals affected by Spinal Muscular Atrophy (SMA). Of this overall population, 37% are living with Type 2 SMA. The estimated incidence rate for this condition is 1 in 15,000 births. Consequently, the expanding occurrence of genetic disorders is a primary factor fueling the development of the nucleic acid and gene therapies in neuromuscular disorders market.
Which Segment Divisions Form The Structure Of The Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market?
The nucleic acid and gene therapies in neuromuscular disorders market covered in this report is segmented –
1) By Disorder: Motor Neuron Diseases, Neuropathies, Neuromuscular Junction Disorders, Myopathies Including Muscular Dystrophies
2) By Therapy: Adeno-Associated Viruses Gene Therapy, Postnatal Gene Therapy
3) By End-User: Hospitals, Specialty Clinics, Ambulatory Surgery Centers
Subsegments:
1) By Motor Neuron Diseases: Amyotrophic Lateral Sclerosis (ALS), Spinal Muscular Atrophy (SMA), Primary Lateral Sclerosis (PLS)
2) By Neuropathies: Charcot-Marie-Tooth Disease (CMT), Hereditary Sensory and Autonomic Neuropathy (HSAN), Peripheral Neuropathies
3) By Neuromuscular Junction Disorders: Myasthenia Gravis, Lambert-Eaton Myasthenic Syndrome (LEMS)
4) By Myopathies Including Muscular Dystrophies: Duchenne Muscular Dystrophy (DMD), Becker Muscular Dystrophy (BMD), Limb-Girdle Muscular Dystrophy (LGMD), Facioscapulohumeral Muscular Dystrophy (FSHD)
Which Trends Are Expected To Shape The Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market?
Companies operating within the nuclear protein in testis midline carcinoma treatment market are concentrating on innovative therapies, particularly combination treatments, to boost their efficacy and improve patient outcomes. Combination therapies are defined as medical approaches that utilize two or more distinct drugs or methods simultaneously to enhance their effectiveness and reduce the development of resistance in combating a disease. As an illustration, in July 2025, Zenith Epigenetics Ltd., a biotechnology company from Canada in the clinical-stage, obtained Fast Track designation approval from the U.S. Food and Drug Administration (FDA) for ZEN 3694 when used in conjunction with abemaciclib. This combination is intended for patients with metastatic or unresectable NUT carcinoma who have already undergone at least one prior chemotherapy regimen. This designation aims to expedite both the development and the regulatory review process for treatments addressing serious conditions where medical needs are currently unmet. These therapeutic approaches, including an oral BET inhibitor, specifically target the oncogenic NUTM1 fusion protein that is a driving force behind NUT carcinoma, while abemaciclib, which functions as a CDK4/6 inhibitor, contributes to inhibiting the proliferation of cancer cells.
Which Organizations Are Operating Within The Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market?
Major companies operating in the nucleic acid and gene therapies in neuromuscular disorders market are Pfizer Inc, F. Hoffmann-La Roche Ltd, Sanofi S.A, Novartis AG, Biogen Inc, BioMarin Pharmaceuticals Inc, Sarepta Therapeutics Inc, Ionis Pharmaceuticals Inc, Ultragenyx Pharmaceutical Inc, Regenxbio Inc, UniQure N.V, Généthon S.A, Axovant Gene Therapies Inc, PTC Therapeutics Inc, Wave Life Sciences Ltd, CRISPR Therapeutics AG, Editas Medicine Inc, Helixmith Co Ltd, MeiraGTx Ltd, Cure Rare Disease, Beam Therapeutics Inc, Intellia Therapeutics Inc, Prime Medicine Inc, Arcturus Therapeutics Holdings Inc, Takeda Pharmaceutical Company Ltd.
Access The Complete Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market Report:
Which Region Accounts For The Highest Share Of The Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market?
North America was the largest region in the nucleic acid and gene therapies in neuromuscular disorders market in 2025. The regions covered in the nucleic acid and gene therapies in neuromuscular disorders market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Access Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market Report for Deeper Competitive Insights
https://www.thebusinessresearchcompany.com/customise?id=21233&type=smp
Browse Through More Reports Similar to the Global Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market 2026, By The Business Research Company
Prostate Cancer Nuclear Medicine Diagnostics Global Market Report 2026
Nuclear Medicine Global Market Report 2026
https://www.thebusinessresearchcompany.com/report/nuclear-medicine-global-market-report
Hereditary Cancer Testing Global Market Report 2026
https://www.thebusinessresearchcompany.com/report/hereditary-cancer-testing-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
